initi ow rate solid hold long-term investor
initi coverag varian medic system overweight rate
pt share pull back sinc late januari vs expect order
instal delay stem take long view today believ
posit exceedingli well win global radiat oncolog market
give us confid strong evid manag execut strategi
shift compani revenu mix increasingli toward higher-margin recur sourc
coupl acceler pace equip softwar innov recent
year translat upper-singl digit revenu low-teen ep growth
year follow growth profil would put elit compani
make share solid core hold long-term investor view
execut well innov strateg front manag strateg
posit compani via intern extern invest succeed global
market acceler var innov cycl offer broadest capabl
hardwar softwar portfolio evid success regard past
year includ democrat adapt radiotherapi etho help address end
user resourc gap exist emerg market broaden compani
capabl multidisciplinari cancer care intervent oncolog
high confid improv gm trajectori recur revenu mix
factor initi manag focus drive stronger mix
recur higher-margin softwar servic sale believ cusp
multi-year expans gm time wed expect multipl share
trade reflect improv financi visibl accompani dynam
weigh near-term perform fulli expect linac order
placement delay across globe hospit redirect resourc cope
priorit capit spend press area need
doesnt alter posit long-term view balanc long-term
optim point near-term uncertainti elect take
long view believ posit well post-covid rebound occur
specif see low-teen normal ep growth along market
lead radiat oncolog presenc make solid core hold
investor initi coverag overweight rate establish
pt share valuat base multipl ep project
largest player radiotherapi market offer hospit custom full
rang hardwar softwar servic solut run radiat oncolog depart
ep
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
acceler innov cycl recent year address end user resourc gap
histori continu rais competit bar make hardwar softwar system
technolog advanc etho hyperarc rapidplan also strateg work
make radiotherapi afford access custom around world halcyon tech-
enabl servic platform strateg effort work compani advantag
radiat peer narrowli focus resourc make therapi sophist
allow grow market europ recent year well maintain
insid track captur major new linac sale fast-grow emerg market china
india
busi toward higher-margin recur revenu activ
manag strateg purpos shift var busi mix toward higher margin
recur revenu sourc recent year includ increas mix oncolog
softwar servic revenu margin accret product launch china-manufactur halcyon
etho system recent acquisit intervent oncolog busi
emphasi translat increas financi predict multi-year expans path
gm believ equat higher multipl investor will pay
stock time
see numer catalyst still horizon var innov engin combin vari
regulatori approv timelin intern market make multi-year launch cadenc
compani roll new system product upgrad next year believ recent
approv etho ce mark clearanc halcyon china soon-to-com
approv etho china japan help oncolog system order growth remain
upper-singl digit least next year believ mani investor larg
understand grow contribut china linac quota india agreement tata
believ potenti order contribut two market isnt fulli appreci street
increas sophist capit deploy execut incent plan realign
last coupl year focu econom profit measur busi valu creation
dub varian valu add move led opinion sophist approach
evalu organ inorgan invest enabl manag appropri balanc
growth profit philosoph shift measur resourc alloc earli
evid success model give us confid manag abil hit
financi target outlin late investor day
top quartil ep grower believ low-doubl digit mid-teen ep compound-annual-growth-rate
sustain share next year acceler what histor
upper-singl digit earn growth correct outlook would put stock
elit compani mid- large-cap franchis confid level long-term
earn growth deserv premium valuat view that balanc today
lack near-term order revenu visibl stem price
target establish today base upon multipl ep project
var five-year averag peer current trade median
risk posit outlook relat disrupt order revenu clear
obviou concern multi-national compani global manufactur
suppli chain network coupl divers geograph revenu mix manag updat
march period-end revenu guidanc disrupt apac itali
mideast take opportun incorpor anticip order profit
pressur impact like persist balanc septemb period-
end resourc attent across impact countri divert
page
press need contain manag diseas specif incorpor sharp
declin order revenu across var report region
turn less bad albeit still declin y/i basi america emea
encouragingli though convers manag recent week suggest condit
china start improv january/februari low understand impact
manufactur suppli chain fairli limit date exclus
manufactur halcyon etho beij facil sourc compon varieti
supplier across globe
risk stock investor need respect shift reimburs dynam
radiotherapi market well possibl new competit launch
disrupt market next month regard former propos
implement sizabl chang radiotherapi reimburs variou time past decad
move creat pocket order uncertainti investor past mani
investor close name awar current radiat oncolog apm propos
recent exampl larg chang often period reimbursement-rel
uncertainti addit risk discount share may appli
competit launch activ somewhat quiet recent year player elekta
acut focus develop launch mr linac elekta clear
recent confer public forum new competit launch expect year
formal launch origin slate estro launch time uncertain light
postpon estro late july/earli august sens plan launch elekta
could bit competit respons var high-throughput value-ori halcyon system
fare well three year avail market also dont want ignor
mr linac categori given superior soft tissu imag clinic outcom afford
technolog given effort elekta shorten treatment time develop
end-market interest build grow bodi clinic data establish stronger reimburs
varian medic system headquart palo alto ca oper lead multi-
disciplinari cancer compani share posit manufactur radiat oncolog
equip investor know today trace root compani call varian
associ found group scientist tie stanford univers earli innov
compani revolv around klystron high-pow x-ray tube technolog
ultim integr compani particl therapi effort began take shape
time varian associ develop three distinct busi segment size health
system instrument semiconductor equip decis made split
three franchis separ publicly-trad compani took effect spring led
compani health system unit becom revenu
compani time sell radiotherapi equip variou x-ray product format
varian medic compani base around focus x-ray technolog guid compani
invest capit alloc next year manag announc may
plan implement new round refocus effort spin imag compon
franchis name enabl varian medic varex focu resourc
manag attent respect busi also import consider
varian medic allow compani oper unencumb market dynam weigh
imag compon franchis year lead announc spin relianc
purchas larg medic imag custom busi sensit fx
custom domicil outsid etc
page
evolut refocus varian medic system
today gener revenu annual three oper segment
vast major come compani market-lead oncolog system franchis
compani oper largest global provid radiat oncolog product servic
segment account company-wid revenu remaind compani
revenu gener sale servic proton therapi equip proton solut
sale product use intervent oncolog set discuss element
segment later note high level note compani boast
instal base linear acceler softwar instal
backlog sit billion
varian busi mix oncolog system franchis strength
briefli regard compani core radiat oncolog franchis oncolog system note
hold domin share market order revenu instal base
perspect includ strong grow equip softwar servic offer across
develop develop market review radiat oncolog market dynam
radiat oncolog market competit section note offer quick glimps
current market presenc held player well var market share
page
radiat oncolog market var top end market
oncolog system repres var primari sourc revenu company-wid order
sale profit oper princip radiat oncolog end market
wide recogn physician hospit execut industri leader respect
technolog innov custom servic high level show
fairli balanc geograph exposur revenu come america
emea apac similarli although mani investor commonli perceiv
princip larg capit equip compani believ common misconcept
less half oncolog system revenu trace back equip hardwar
disclos present file materi shift year ago
segment revenu tie equip
portfolio perspect maintain comprehens hardwar softwar
servic offer across industri end-to-end solut enabl hospit custom run
high-qual effici radiat oncolog depart weve seen hardwar portfolio evolv
year day clinac trilog novali year ago portfolio
stand today truebeam vitalbeam edg halcyon etho said
softwar side hous offer rapidarc rapidplan eclips veloc
insight aria oncolog hyperarc other intend improv patient
clinic outcom enabl effici treatment deliveri better organize/manag data
hardwar side var full linear acceler product suit fairli customiz solut
allow hospit acquir system best fit need halcyon exampl
page
introduc allow hospit abil system quickli instal minim time
two week instal commiss time averag allow high throughput hospit
radiotherapi case manag point halcyon user reach patient
treat singl day truebeam consid var versatil system treat broad
rang cancer case leverag advanc imag modal safe deliv highli
accur treatment primari reason still fast-grow platform compani ten year
post launch hospit interest shift toward adapt therapi treatment regimen
least portion case concern high cost commerci avail mr linac
could opt var recent introduc etho system leverag artifici intellig
multi-mod imag enabl daili treatment adapt still deliv care tradit
minut treatment slot show exhibit var system slot
asp rang run low entry-level system high end
investor think new product could mean var order revenu
growth trend time coupl item worth note first histor perspect
long consid new c-arm solut truebeam vitalbeam etc necessarili
wholli increment rather offer asp benefit and/or afford possibl new
hardware/softwar upgrad path time said anoth way weve histor consid new
product cycl support compani growth profil allow growth remain
market rate plu minu coupl point given year believ howev
halcyon introduc estro etho introduc astro provid
greater increment order revenu argument c-arm system princip
believ halcyon offer cost effect solut emerg market custom could enabl
captur sale may otherwis gone differ player etho enter
afford option adapt therapi field clinic interest rapidli grow
didnt previous competit offer speak specif halcyon trend sinc
introduct check suggest approxim order system
new system trend believ appear indic futur custom mix sit three year
launch platform
page
strong new socket growth attribut halcyon
stop provid halcyon unit-specif order
mind attempt frame investor impact recent upcom launch
product approv could var order growth profil
etho avail etho receiv approv mid-februari clearanc
allow offici begin book order system well begin
book revenu system instal first instal alreadi underway
price tag halcyon-rel convers run recent
approv translat immedi order america context america
order growth would see tailwind everi new etho order book also
dont lose sight posit margin implic china-manufactur software-
heavi system instal ramp next month
halcyon approv china week ago receiv nmpa approv
china add kv imag halcyon system complet guesswork estim
approv might mean system order market manag allud
past launch anoth elbow growth compani importantli
current class quota china still earli stage execut approv
halcyon could posit well captur even greater proport order tie
issu licens
etho china halcyon approv suspect secur nmpa approv
etho primari focu var regulatori team china unit
opportun etho china smaller halcyon manag
express confid us multipl time sinc etho introduct last fall
system absolut well receiv chines market approv
respect recent perform inclus guidanc updat
segment order revenu grown respect ttm basi includ
growth recent contributor var growth fairli balanc
well recent quarter geograph product categori perform fairli solid across
compani report structur manag specif call multi-facet momentum
late includ record unit sale truebeam halcyon grow softwar uptak especi
rapidplan hyperarc competit win emea healthi traction tata relationship india
solid increas io franchis
page
sinc launch nearli three year ago approxim halcyon order increment prior halcyon ordersquarterli halcyon ordershalcyon launch estro may ce mark fda secur june halcyon withkv imag showcas estro april fda secur may receiv china nmpa approv exhibit
oncolog system overview present
look beyond compani bread butter oncolog hardwar softwar busi
worth devot bit time highlight compani acquisit cancer treatment
servic intern largest acquisit compani histori deal valu
final june acquisit initi met skeptic street portion
ctsi revenu revolv around oper ten multidisciplinari cancer center india categori
potenti outsid comfort zone averag investor profil
believ introduc addit oper busi capit financ risk howev
quickli becam clear cancer center oper much secondari jewel
tech-en servic platform effect posit address skill
resourc gap face mani emerg market custom platform dataset
acquir transact abl offer custom ai-driven servic offer
oncolog servic oaa treatment plan servic segment
servic qualiti assur servic help autom tradit manual
process address key bottleneck skill physician physicist prevent emerg
market custom acquir new technolog dynam believ went
underappreci time deal announc still today isnt fulli recogn either
greater eas facilit new linac equip purchas emerg market custom
arent abl appropri staff center necessari skill profession
develop market interest ai-driven platform autom long manual
element plan care deliveri
ctsi diagnost clinic support deliveri capabl
page
oncolog order revenuelinac servicesclin deliverydiagnost servic medic physic medic oncolog histopatholog clinic dosimetri radiat oncolog molecular patholog oncolog surgic oncolog cytogenet multidisciplinari surgeri cytometri bmt program immunoassay cancer marker train educ op procedur nextgen sequenc clinic workflow ip oncolog carectsi oncolog platform clinic pathway decision-support tool
report standpoint fall oncolog system segment revenu
specif slot servic sub-seg ctsi-rel revenu ad
first two full quarter contribut model equat
contribut oncolog servic cc revenu growth closer total oncolog system
cc revenu growth level believ reason project continu next
coupl quarter opinion experi modest impact
healthi growth contribut
final comment oncolog system segment wed remiss didnt devot least
attent propos radiat oncolog ro model episodic-bas payment
bundl model propos last juli one sent wave investor commun
last summer lot written discuss respect ro model sinc
introduc there shortag commentari industri particip hospit
manufactur trade organ advocaci group etc past sever month
remind key detail regard propos ro model includ bundl payment base
patient cancer diagnosi would cover radiotherapi servic furnish episod
cancer type cancer type account nearli radiotherapi episod
particip would mandatori provid locat yet-to-be-announc cbsa
mandatori particip expect account episod payment rate would
split two compon profession technic payment would part link
qualiti perform clawback measur model implement origin propos
januari april year
worth note investor health polici council vice-chair astro discuss recent
late februari final version ro model still expect releas year
advis practic prepar accordingli mind manag echo similar
expect recent call rule move final review stage omb
mid-march investor fulli expect final rule altern payment model releas
point come month unclear final rule restructur
payment system impact hospit believ hand origin propos measur could
potenti roll back and/or modifi less burdensom provid includ less sever
payment cut fewer hospit includ model model voluntari period
time delay phased-in approach model deploy order give
particip hospit appropri amount time coordin train staff new bill
code dynam
also unclear may impact time implement hospit across
countri alreadi strain respond pandem lead astro advoc delay
page
oncolog servic revenu growthcontribut total oncolog revenu growth
implement wouldnt surpris issuanc final rule delay
month crisi subsid similarli envis implement ro
model also delay sever month wouldnt surpris see januari set
new implement date
stock perspect weve seen meaning chang reimburs
landscap past expect near-term deferr linac order would prove
temporari hospit take time determin best way navig fee schedul
best maxim roi radiat oncolog depart importantli wed highlight
model go form close origin propos design believ
compani posit well radiotherapi player shift fee-for-servic
value-bas scheme primarili given product effici focu compani across
product-develop capit alloc activ recent year halcyon etho
etc also import investor keep mind industri discuss concentr care
deliveri shift hypofraction could unfold value-bas care environ believ
var linac portfolio well-suit address custom need particularli high-precis
srs/sbrt edg unit versatil truebeam system
keep discuss var two segment fairli brief note primarili share
trade almost exclus perform anticip futur trend oncolog system
segment well discuss segment offer potenti drive improv financi
perform proton solut particular hold long-term clinic potenti within
nascent field flash therapi
clinic perspect remind investor proton therapi compar advantag vs
tradit radiotherapi util photon deposit ioniz radiat dose directli
tumor site known bragg peak limit typic entri wound exit wound
commonli damag healthi tissu tradit radiotherapi precis form therapi
limit healthi dose damag made proton therapi ideal option spinal lung head
neck retin brain tumor well treat pediatr tumor without expos
patient neg side effect tradit radiotherapi higher risk radiation-rel
secondari tumor develop higher risk stunt growth
page
var probeam precis deposit dose deliv proton therapi
enter proton therapi busi acquisit accel instrument
year later segment continu struggl profit hand reason
import end market overal fairli slow adopt proton therapi given
system cost/invest return factor attempt tackl challeng time
move exclus multi-room offer cost much equip
alon much entir project single-room system run closer
equip introduc system enhanc allow improv patient throughput
even particip financ effort site
effort seen grow proton custom base site oper
current variou stage construct equip instal
total repres backlog futur hardwar revenu million although revenu
associ backlog like prove variabl compani increasingli recogn
service-rel revenu new equip instal factor help improv segment
profit given stronger margin profil servic revenu rel proton equip
margin point one hand discuss later note factor leav us
comfort project roughli gm expans
page
due lumpi unpredict natur model futur proton order
may sever quarter away see proton segment turn break-even
ebit basi outlook busi turn intrigu sinc astro
unveil early-stag effort field flash therapi flash theoret idea
deliv patient ultra-high level dose precis fashion treatment session
therapi possibl util proton equip base earli studi signific
dose escal speed deliveri result strong tumor control limit side effect
reduc differenti gene express vs convent radiotherapi reduc skin toxic
clear flash-rel studi thu far pre-clin animal-bas studi although
check suggest in-human var-sponsor studi could begin next quarter two even still
flash therapi creat intrigu catalyst segment sever year neglect
street
respect model financi contribut segment take conserv
approach model order dont project unannounc order segment
princip due inher predict challeng also assum revenu
remain window quarterli basi next year service-
relat revenu expect gradual rise new center treatment room brought on-line
enter intervent oncolog market via acquisit endocar
embol bead asset sinc acquisit revenu acquir
busi report newli creat segment var financi
theyr current busi report segment one number item
reflect manag shift approach becom multi-disciplinari cancer care provid io
may evid investor given repres entir new busi line
separ compani core radiotherapi end market
briefli io market manag peg market size grow
annual mid- upper-singl digit pace product solut constitut market
leverag treat cancer tumor one two main mean thermal ablat
embol former extrem cold heat concentr tumor site mean
burn freez cancer latter involv target placement bead patient
blood vessel starv tumor blood flow
particular note manag move decis execut two separ
transact last year span coupl month begin build presenc
categori give compani offer number io sub-categori cryoablat microwav
ablat bland bead embol drug-elut chemo embol
investor skeptic wake deal high multipl paid asset addit personnel
page
infrastructur invest requir move outsid var radiotherapi expertis
believ sever key posit investor shouldnt overlook continu invest
build io presenc intervent oncolog asset feed manag strategi
increas consumables/recur revenu profil compani io-rel revenu
prove accret endocar bsx-bead acquisit lap contribut
organ growth growth accret revenu also bring along accret gross margin
alreadi see io gm settl io give
manag platform futur attract capit alloc path vs what limit
 option var core radiat oncolog market
intervent oncolog gross margin step
market
radiat oncolog market measur piper sandler sit billion size
inclus equip softwar servic provid variou player discuss earlier
control command share global market sweden-bas elekta
second-largest radiotherapi equip manufactur account market
two compani make near duopolist market hand player
investor radar includ cover
market growth perspect note radiat oncolog market sale grown
respect compound-annual-growth-rate compound-annual-growth-rate constant currenc basi past five year per
market model notabl market growth move modestli higher past coupl year
combin healthi macro backdrop signific radiotherapi invest made
number emerg market name china india improv cadenc new product
offer across industri especi lift overal market growth upper-
singl low-doubl digit histor mid-singl digit grow market
page
targetd announcedd closedbusi descriptiond valuerevenu acquiredoth detailsendocar lead provid hardwar softwar solut support cryoablat microwav ablat compani lead product cryocar cs fulli integr treatment system cryotherapi leader embol therapi treat liver cancer china lead product caligel calibr resorb gelform use embol agent treat liver cancer million non- ep bead boston acquir boston scientif portfolio microspher oncozene/embozen tandem bland embol embozen bead product treat arterioven malform hypervascular tumor product regulatori cleranc countri world-wide opeart acquir transact transit servic agreement place manufactur distribut place million non- ep oncolog gm step build ian intervent oncolog solut commerci team includ direct sale distribut networkexpandcryotherapi microwav product sale new market worldwideinvestin extend varian innov legaci intervent oncolog market segmentleveragevarian softwar expertis build differenti solut suit offer exhibit
radiat oncolog market order revenu compani
fruit var acceler pace innov
respect unit instal across market estim approxim linear
acceler global repres instal instal market
share follow fairli consist revenu share describ elekta instal
number follow note
includ estim siemen system believ may still use across
world figur close linac instal base prior siemen
exit market
page
linear acceler instal base manufactur
competit perspect although elekta focus primarili launch activ
market develop mr linac system compani instal base reput
especi softwar shouldnt dismiss allud earlier weve heard rumbl
elekta may launch near term value-ori system featur small footprint eas instal
addit detail fairli limit commentari weve glean elekta manag
past regard system echo featur set separ var
halcyon competitor rfp tender negoti capabl high qualiti imrt/igrt
high patient throughput value-bas price point hope learn detail
come month regard system leav point investor keep
back mind
also worth touch var recent launch etho fit adapt therapi
competit landscap concept behind etho leverag multipl imag modal ct
pet mr power ai order allow clinician adapt deliv therapi need
complet full adapt treatment tradit treatment slot clinic
drawback rel adapt therapi system market name mr linac elekta
etho doesnt abil track tumor movement real-tim therefor
cant accomplish autom beam gate turn radiat beam depend tumor
locat relat pre-determin treatment margin critic structur clinic
mean treatment dose deliv etho may precis therefor may result
greater toxic deliv healthi tissu howev advantag ai/softwar
autom allow short time-on-couch patient minut vs minut
mr linac system cost instal time also skew var favor week instal
timelin vs system cost sever month instal process mr linac non-academ
hospit tradit econom sensit total system roi matter
great deal believ etho screen well look adapt therapi tool
add treatment suit
high respect technolog compani believ
help advanc forward clinic care industri recent year relat
howev dont believ either yet scale portfolio breadth innov budget pose
threat var multi-year growth potenti vray elekta mr linac technolog
well pre-commerci technolog develop reflexion bgrt system
exampl repres area monitor long-term clinic commerci potenti especi
stronger reimburs level higher-end technolog provid point
futur believ believ lead end-to-end oncolog
equip portfolio global market
page
side note cover space year frequent ask question
whether medic imag player may someday attempt enter radiat oncolog
portion broader hospit equip market effort leverag exist relationship
cross-sell/bundl equip sale custom certainli possibl never want rule
deep-pocket player muscl market consid strong multi-year
growth tail note mani exist medic imag player presenc
radiat oncolog past coupl decad make strateg decis eventu
exit market refer list includ ge exit sold servic right
philip sold radiotherapi busi elekta mitsubishi exit sold servic right
recent siemen exit retain servic announc cross-
sell partnership case understand parent
compani found d/innov effort radiotherapi equip softwar
high rel standard medic imag custom servic need necessit
unit scale order gener appropri roi parent said wouldnt ever
rule possibl one aforement capit equip compani
portfolio player seek presenc radiotherapi identifi either elekta
target would effect bring strong establish platform broad product suit
establish servic infrastructur sever thousand exist custom
section follow step brief review key financi metric note
manag implement formal long-rang plan company-host investor day
month ago includ plan expect deliv revenu growth
compound-annual-growth-rate base manag origin revenu guidanc
om vs guidanc cash oper equat
ebitda show weve updat figur manag revenu guidanc updat
pair revenu om target togeth basic below-the-lin
assumpt modest interest/oth improv tax rate stabl share count unchang
current level arriv impli ep compound-annual-growth-rate share worth
note light recent revenu guidanc updat manag reiter
confid commit deliv revenu compound-annual-growth-rate emphas
near-term revenu disrupt like captur come quarter countri
healthcar system abl return normal oper practic fair financi
like take meaning step lower beyond manag revenu guidanc reduct
given signific spread viru overwhelm hospit healthcar system
 across europ
strong growth forecast long-rang
page
growthrevenu cagradjust cagradjust ebit margin midpointep cagrcash project base guidanc revenu project base manag updat revenu guidanc ep project assum stabl tax rate approxim share outstand growth base guidanc long-term cash flow guidanc ebitda low high piper sandler estim growth base guidanc midpoint order backlog
order specif order oncolog system franchis repres item investor
focu attent quarter-to-quart basi princip order offer best
insight futur financi perform ww ttm cc oncolog order growth sit
recent includ ttm cc order growth america emea
apac opinion varieti factor help order growth remain solid
mid-singl digit level sever consecut quarter includ healthi macroeconom
backdrop recent year grow dollar alloc radiat oncolog care fairli
stabl reimburs dynam lead apm propos larg capit
commit numer emerg market especi china india solidli
consist hardwar softwar innov pipelin help compani win
entir new establish competit account
near-term perspect show order outlook attempt account
custom purchas deferr expect result shift resourc priorit amidst
outbreak specif estim divert attent also similar delay
tender-rel activ could result quarter period order contract across
var geograph segment model project cc order declin
america balanc emea apac
order strength past year help backlog steadili grow time reach
billion end respect
figur end fiscal year end typic repres near-
term peak absolut backlog level steadi mid-singl digit y/i growth seen
compani backlog past sever quarter provid visibl similarli healthi
growth compani product next two year order book backlog
deem shipment revenu recognit occur within two year even spite recent
placement deferr final note mix backlog current sit
oncolog system proton solut there compon
backlog other/intervent oncolog franchis
page
gener annual revenu billion vast major stem
compani oncolog system segment revenu increas constant currenc
basi vs organ exclud contribut acquisit close second
half fiscal year strength set continu nice manag origin
guid revenu growth organ growth unsurprisingli mani
compani done past coupl month manag last month trim
report revenu guidanc impli organ account system placement
deferr market sever impact still solid growth fluid covid-
situat around globe make near-term outlook admittedli somewhat uncertain
fulli expect reduct withdraw guidanc account significantli greater
spread western europ sinc manag guidanc updat last
strong pace revenu growth past sever quarter healthi growth outlook
incorpor manag long-rang plan larg part function increas
spend past year help drive broader technolog adopt increas
win rate custom sustain attract revenu growth also
support continu purpos shift toward recur revenu sourc past
year specif innov shift contract structur softwar busi line
diversif manag shift revenu mix tie lumpier
hardwar softwar licens closer today
page
grow shift predict recur revenu sourc
contribut confid recur revenu shift grow mix busi
see categori saa agreement offer io
busi growth linac servic contribut regard latter less discuss
impress part var success growth past year acceler
system placement time averag increment system ad instal
base quarter jump averag increment system per
quarter sinc acceler placement activ concert part var
busi strategi drive softwar servic revenu gener year follow
initi instal acceler linac instal begin contribut increment
servic revenu provid one-year warranti system
hospit engag servic maintain system
acceler system placement coupl order backlog
strength past six quarter lead us believ servic revenu growth oncolog system
similarli acceler next sever quarter context potenti
contribut weve histor referenc annual servic contract valu total system
asp linac may carri annual service-rel revenu
var newer system sale boast higher asp higher servic contract attach rate
legaci system make simpl assumpt regard factor dont believ
stretch argu increment servic revenu figur
would provid increment tailwind oncolog company-wid revenu
page
sale softwar licensesservic exhibit
instal base growth acceler translat correspond servic revenu
growth acceler
margin trend flux last coupl year part due compani
separ result less corpor overhead leverag immedi follow
spin-off also varieti factor impact profit throughout much notabl
 /china tariff also fx slight a-rel dilut geograph mix softwar deploy
cost total adjust gm om finish respect
y/i line
gross oper margin trend sinc
page
includ manag long-rang financi target referenc expect
om expand approxim midpoint measur
wouldnt surpris compon manag plan investor histor
familiar stori financi model question particularli manag
outlin plan maintain elev pace spend target sale vs
sale alreadi run fairli lean respect sale vs mani
capit equip peer sit closer sale dont disagre avail
opex leverag appear limit fulli buy likelihood gross margin
expans key driver profit improv next sever year given host
factor see come togeth contribut includ follow
increas mix halcyon etho manag note halcyon boast gm
accret var overal gm profil suggest margin delta
halcyon linac etho serv widen gap given
signific asp premium vs halcyon etho vs halcyon
larg tie ai/softwar includ etho
potenti addit manufactur china beyond halcyon etho
check suggest manag implement capabl past year
manufactur entir linac fleet china includ compani best-sel
faster growth oncolog softwar servic vs hardwar dynam
posit mix tailwind broader organ
 margin accret includ gm intervent oncolog
above-compani gm service-ori franchis
increas proton servic revenu also modest posit margin
implic proton servic revenu look like grow year
ep perspect note gener adjust ep growth
fairli modest vs level y/i held back number non-oper factor
notabl /china tariff also fx slight a-rel dilut apples-to-appl
basi estim core ep growth would closer
factor worth noth regard manag guidanc though line item
yet formal updat account impact last month updat
cover revenu mean ep outlook like reset accordingli report
result later month look past evalu expect perform
come year believ low- mid-teen ep compound-annual-growth-rate project street
next year includ midpoint manag long-term financi outlook remain
page
adjust ep consensu ep balanc sheet
var balanc sheet cash gener long point strength suspect
point becom valid come year manag execut long-
term financi plan increasingli shift busi toward higher-margin recur revenu
sourc suspect throw grow pile cash expect point also
feed capit alloc engin believ start hum past coupl year
begin first var balanc sheet note compani exit net cash posit
cash equival compar drawn compani revolv credit
facil leav compani plenti dri powder balanc sheet capac larger
busi seri larger asset made avail purchas absenc
transact howev would expect gradual pay revolv asid
item worth note meaning step work capit weve seen compani
past sever quarter specif inventori risen nearli sinc
compani made invest conjunct acceler pace linac order growth
time-frame inventori build provid fortun benefit near
intermedi term give plenti oper cushion case compani linac compon
suppli chain affect disrupt
shift cash flow guidanc offici call year guidanc
offici updat wouldnt surpris see materi reduct cash
flow guidanc manag report result week revenu strength margin
expans also help cash flow grow meaning next sever year math
suggest long-term plan impli import consid free
cash convers oper fairli limit capital-expenditure need less sale mean
like prove modestli oper cash flow go-forward basi
capit alloc current regim taken bit balanc approach
respect intern invest share repurchas weve alreadi discuss fruit
step infrastructur invest activ earlier note also
touch larger transact made one activ year deal activ
record there also notabl shift philosophi toward share buyback sinc
devot almost exclus repurchas vs past two year
seen repurchas settl rang level buyback enough off-set
normal dilut keep dilut share count stabl move slightli lower time
fulli expect manag continu oper within overarch capit alloc structur
forese futur
shift capit alloc strategi sinc
page
introduc today estim provid line item detail annual
project compar vs street also remind profit
estim sit manag formal guidanc incorpor expect revenu
deferr correspond lost earn stem impact
establish price target today repres multipl
ep project multipl use valu share
averag multipl share trade past five year point believ
reason consid var steadili increas recur revenu improv gm outlook
acceler earn growth profil project busi next year
balanc near-term uncertainti end also note
ntm basi share averag near period time
mean ntm price-to-earnings multipl would conserv equat ep growth
doubl digit mid-teen ep compound-annual-growth-rate impli manag long-rang plan see
ep compound-annual-growth-rate project
attempt neutral swing broader market past coupl month var
multipl unsurprisingli contract see second set chart
specif var ntm price-to-earnings ntm multipl rel fallen
respect five-year averag gener rang weve seen share trade past
page
million valuegrowth y/i valuegrowth y/i revenu gross gross ebit adjust ebit margin ep gross gross ebit gross gross ebit sandlerstreet manag updat report revenu guidanc account expect impact formal address guidanc line item
three year valuat standpoint part rel multipl under-perform
share lead us believ investor alreadi bake share price
challeng end-market demand least next coupl quarter depth
recess like dictat quickli share recaptur lost absolut rel multipl
will earli call today recommend investor stock
recent pullback creat favor entri point compar histor averag
rel peer multipl repres slight discount vs ntm price-to-earnings multipl
larg cap peer current trade var normal upper-singl low-doubl
digit revenu growth profil look sustain consid numer gross margin lever
manag dispos next sever year believ low-doubl digit upper-
teen ep growth target prove achiev would put elit
compani said also believ slight discount vs peer current environ
appropri consid better near-term busi visibl compani maintain
procedure-rel recur revenu busi model
page
ntm price-to-earnings past yearsntm past yearsrel vs ntm price-to-earnings past yearsrel vs ntm past price-to-earnings rel rel paverag exhibit
market cap valuat april
hallmark year strength manag team well-
respect group across radiat oncolog industri group includ ceo wilson
role sinc sinc previous serv
presid compani oncolog system franchis
current presid oncolog system chri toth presid os sinc
sinc extend well-round board director possess deep healthcar
technolog expertis weve also fan cfo mike bruff sinc first join
serv varieti senior financ strategi role year believ long-
term orient investor confid wilson bruff team deliv strong above-
market return come year
page
fisher scientif dickinson surgic scientif lifesci laboratori biomet hold technolog sirona hold discount vs peer growthep growthcompanytickermarket capntm price-to-earnings inc
million
sale
amort cog
amort opex
earn non-controlling interest
net incom loss attribut varian
revenu report
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
